Once introduced, Novo Nordisk will have its complete semaglutide portfolio in India, providing a range of treatments to address diverse patient needs the already launched oral semaglutide for diabetes and advanced obesity management through Semaglutide 2.4 mg injection and the soon-to-be-launched Semaglutide injection in 0.25, 0.5 & 1.0 mg strengths for type 2 diabetes
How to do quantile normalization correctly for gene expression data analyses
Questions about insurance coverage remain
They are now part of a broader medical discussion about obesity, insulin resistance, cardiovascular risk, fatty liver disease, inflammation, body composition, appetite signaling, and long-term metabolic health
We also offer value-packed membership plans and packages for clients interested in ongoing wellness care